Effect of piracetam in preventing delirium in ICU patients

Investigating the effect of piracetam compared to placebo in preventing delirium in patients admitted to the intensive care units

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240105060618N1

Enrollment

Registered

2024-04-12

Start date

2024-04-18

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium. Delirium due to known physiological condition

Interventions

Intervention 1: Control group: Placebo (1 pill every 8 hours for 7 days). Patients in this group will receive a placebo tablet with a glass of water every 8 hours. This intervention continues from the

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age 18 to 80 Consent to participate Medical ICU case

Exclusion criteria

Exclusion criteria: Pregnancy COVID-19 patients Surgical and burn ICU cases APACHE score >28 in the ICU admission

Design outcomes

Primary

Measure	Time frame
Delirium (positive confusion assessment method). Timepoint: The first 7 days of ICU admission. Method of measurement: Confusion assessment method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactYeganeh Abedipor

Tehran University of Medical Sciences

yeg.abedipor@gmail.com+98 912 805 0154

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026